12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GFT505: Phase II data

The single-blind, crossover, French Phase II GFT505-210-6 trial in 22 insulin-resistant patients with abdominal obesity showed that once-daily 80 mg oral GFT505 met the co-primary endpoints of significantly increasing insulin sensitivity in the liver and peripheral tissues from baseline to week 8 vs. placebo. Specifically, GFT505 significantly reduced insulin-induced hepatic glucose production by 0.86 mg/kg/min vs. 0.63 mg/kg/min for placebo (p=0.006), and significantly...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >